Peroxisome proliferator-activated receptor alpha agonist suppresses neovascularization by reducing both vascular endothelial growth factor and angiopoietin-2 in corneal alkali burn

32Citations
Citations of this article
20Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

We investigated the effect of a peroxisome proliferator-activated receptor alpha (PPARα) agonist ophthalmic solution in wound healing using a rat corneal alkali burn model. After instillation of a selective agonist of PPARα, fenofibrate, onto the burned cornea, PPARα-positive cells were observed in vascular endothelial cells, and there was upregulation of mRNA of PPARα in corneal stroma. Fenofibrate suppressed expression of neutrophils and macrophages during the early phase, and development of neovascularization and myofibroblast generation during the late phase. Fenofibrate reduced not only mRNA expression of vascular endothelial growth factor-A but also angiopoietin-1 and angiopoietin-2. Furthermore, fenofibrate suppressed scar formation by reducing type III collagen expression. These data suggest that a PPARα agonist ophthalmic solution might be a new strategy for treating corneal wounds through not only anti-inflammatory effects but also by preventing neovascularization.

References Powered by Scopus

Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators

3210Citations
N/AReaders
Get full text

Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis

3120Citations
N/AReaders
Get full text

mPPARγ2: Tissue-specific regulator of an adipocyte enhancer

2050Citations
N/AReaders
Get full text

Cited by Powered by Scopus

PPARs and tumor microenvironment: The emerging roles of the metabolic master regulators in tumor stromal-epithelial crosstalk and carcinogenesis

49Citations
N/AReaders
Get full text

Sleep deprivation induces dry eye through inhibition of PPARα expression in corneal epithelium

43Citations
N/AReaders
Get full text

PPARα agonist oral therapy in diabetic retinopathy

34Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Arima, T., Uchiyama, M., Nakano, Y., Nagasaka, S., Kang, D., Shimizu, A., & Takahashi, H. (2017). Peroxisome proliferator-activated receptor alpha agonist suppresses neovascularization by reducing both vascular endothelial growth factor and angiopoietin-2 in corneal alkali burn. Scientific Reports, 7(1). https://doi.org/10.1038/s41598-017-18113-3

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 6

43%

Researcher 4

29%

Lecturer / Post doc 3

21%

Professor / Associate Prof. 1

7%

Readers' Discipline

Tooltip

Medicine and Dentistry 6

46%

Pharmacology, Toxicology and Pharmaceut... 3

23%

Biochemistry, Genetics and Molecular Bi... 3

23%

Neuroscience 1

8%

Save time finding and organizing research with Mendeley

Sign up for free